PPARγ and the PPARγ coactivator (PGC)-1α, which play key roles in various metabolic disorders, are also known to be targeted by SIRT1 [16,17], but the effects of telmisartan on SIRT1- and PPARγ-signaling remain unclear. This evidence concerns the gene SIRT1 and metabolic disease.